DiaSorin (OTCMKTS:DSRLF) Shares Gap Down – Here’s What Happened

Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF) gapped down before the market opened on Monday . The stock had previously closed at $80.40, but opened at $77.58. DiaSorin shares last traded at $77.58, with a volume of 20 shares changing hands.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Zacks Research upgraded shares of DiaSorin to a “hold” rating in a research report on Tuesday, May 12th. Piper Sandler initiated coverage on DiaSorin in a report on Thursday, June 11th. They issued a “neutral” rating on the stock. Deutsche Bank Aktiengesellschaft cut DiaSorin from a “hold” rating to a “sell” rating in a report on Wednesday, June 17th. UBS Group lowered DiaSorin from a “buy” rating to a “neutral” rating in a research report on Thursday, April 9th. Finally, BNP Paribas Exane downgraded DiaSorin from a “neutral” rating to an “underperform” rating in a research report on Tuesday, July 7th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, DiaSorin currently has an average rating of “Hold”.

DiaSorin Price Performance

The business’s fifty day simple moving average is $76.08 and its 200-day simple moving average is $76.38.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.